2023
DOI: 10.1186/s13023-023-02959-0
|View full text |Cite
|
Sign up to set email alerts
|

A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex

D. Mammadova,
J. Vecko,
M. Hofmann
et al.

Abstract: Background Tuberous sclerosis complex (TSC) is a rare multisystem disorder caused by mutations in the TSC1 or TSC2 gene. More than 90% of patients with TSC develop neurological and/or neuropsychiatric manifestations. The aim of the present study was to determine the developmental and cognitive long-term outcomes of pediatric TSC patients. Methods This cross-sectional, monocenter study included pediatric TSC patients who received multidisciplinary l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 54 publications
(129 reference statements)
0
1
0
Order By: Relevance
“…In addition, simplex cases are more likely to involve TSC2 pathogenic variants, while inherited pathogenic variants are more evenly split between TSC1 and TSC2 [ 64 ]. Furthermore, TSC2 pathogenic variant carriers are at greater risk for renal malignancies, cardiac rhabdomyomas, intellectual disability, infantile epileptic spasms, and drug-resistant epilepsy [ 81 , 87 , 88 , 89 ]. In infancy, up to 24 months of age, TSC2 pathogenic variant carriers are at higher risk for significant developmental delays [ 90 ].…”
Section: Summary Of Genotype–phenotype Correlations For Tscmentioning
confidence: 99%
“…In addition, simplex cases are more likely to involve TSC2 pathogenic variants, while inherited pathogenic variants are more evenly split between TSC1 and TSC2 [ 64 ]. Furthermore, TSC2 pathogenic variant carriers are at greater risk for renal malignancies, cardiac rhabdomyomas, intellectual disability, infantile epileptic spasms, and drug-resistant epilepsy [ 81 , 87 , 88 , 89 ]. In infancy, up to 24 months of age, TSC2 pathogenic variant carriers are at higher risk for significant developmental delays [ 90 ].…”
Section: Summary Of Genotype–phenotype Correlations For Tscmentioning
confidence: 99%